An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) - Full Text View -...
This phase I trial studies the best dose of radiation therapy in treating patients with locally advanced non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy, such as stereotactic body radiation therapy (SBRT), that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. SBRT has been shown to provide excellent results when used in early stage lung cancer, but has not yet been applied to patients with more advanced disease ...https://clinicaltrials.gov/ct2/show/NCT01711697?recr=Open&cond=%22Carcinoma%2C+Non-Small-Cell+Lung%22&rank=19
DSpace at EWHA: Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA...
An increasing number of chromosomal aberrations is being identified in solid tumors providing novel biomarkers for various types of cancer and new insights into the mechanisms of carcinogenesis. We applied next generation sequencing technique to analyze the transcriptome of the non-small cell lung carcinoma (NSCLC) cell line H2228 and discovered a fusion transcript composed of multiple exons of ALK (anaplastic lymphoma receptor tyrosine kinase) and PTPN3 (protein tyrosine phosphatase, nonreceptor Type 3). Detailed analysis of the genomic structure revealed that a portion of genomic region encompassing Exons 10 and 11 of ALK has been translocated into the intronic region between Exons 2 and 3 of PTPN3. The key net result appears to be the null mutation of one allele of PTPN3, a gene with tumor suppressor activity. Consistently, ectopic expression of PTPN3 in NSCLC cell lines led to inhibition of colony formation. Our study confirms the utility of next generation sequencing as a tool for the ...http://dspace.ewha.ac.kr/handle/2015.oak/222532
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer - Full Text View -...
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early stage NSCLC. Several studies have reported high local control and survival using SBRT in stage I NSCLC patients. SBRT is now an accepted treatment for medically inoperable patients with stage I NSCLC and patients with operable stage I lung cancer are entered on clinical protocols. The purpose of this study is to conduct a phase III randomized study to compare CyberKnife SBRT with surgery, the current standard of care for stage I operable NSCLC ...https://clinicaltrials.gov/ct2/show/NCT00840749?term=cyberknife&rank=6
Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) - Full Text View - ClinicalTrials.gov
This is a Phase 1b pre-operative lung cancer trial wherein patients with operable lung cancer will be treated with RAD001 for 3-4 weeks to study the effects of the novel agent in relevant molecular pathways. The study will also assess the FDG uptake of the tumor at baseline and upon completion of therapy (before surgery) with a PET scan. The safety profile of RAD001 will also be evaluated.. New agents and regimens are urgently needed for lung cancer treatment. With the development of novel agents and small molecules designed to curtail the aggressive aspects of this disease, some progress has been realized. However, much more effort and insight will be required for further real gains to be made. We propose that studying the mammalian target of rapamycin (mTOR) axis, known to be abnormal in non-small cell lung cancer (NSCLC), and translating that knowledge into therapeutic adjustments can lead to meaningful advances in lung ...https://clinicaltrials.gov/show/NCT00401778
British Library EThOS: Genomic biomarkers of recurrence in stage I non-small cell lung cancer
Objective: Lung cancer is the leading cause of cancer-related mortality worldwide. Disease stage still remains the best prognostic factor for patients with localized non-small cell lung cancer. The TNM staging system, however, does not address the heterogeneity of this disease. Sub-classification and identification of distinct prognostic sub-groups within each stage may allow the optimization of clinical trial design and potentially improve outcome. This is a retrospective pilot study, in which we attempt to identify genomic biomarkers predictive of recurrence in stage I lung cancer by analysing copy number (CN) data obtained by next-generation sequencing. Materials and Methods: Ninety eight patients with stage I NSCLC, who underwent elective radical surgery were identified from a tissue bank of 323 tumour samples. Their demographic and surgical data, including their recurrence status were collected and an extensive database compiled. The cases were split ...http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.685230
Non-Small Cell Lung Cancer
... is the most common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer.https://www.cancer.org/cancer/non-small-cell-lung-cancer.html
Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov
Lung cancer is the leading cause of death in the United States as well as worldwide. It is estimated that approximately 215,020 new cases of lung cancer will be diagnosed in the United States in 2008, with approximately 161,840 deaths (1). The great majority of the lung cancers are grouped as non small cell lung cancer (NSCLC), and only 13% as small cell lung cancer. Most patients with NSCLC present with advanced disease (55% with stage IIIB or IV). The overall median survival of patients with advanced NSCLC treated with first line platinum based doublets is less than 12 months (8 10 months) with a 1 year and 2 year survival of 33% and 11%, respectively (2-4). Agents targeting epidermal growth factor receptor (EGFR), matrix metalloproteinase, farnesyl transferase, protein kinase C and retinoic X receptor have so far shown no survival benefit in combination with chemotherapy in advanced NSCLC (5-10).. More recently, 2 trials ...https://clinicaltrials.gov/ct2/show/NCT00934076
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) -...
During induction, participants with nonsmall-cell lung cancer (NSCLC) received up to 6 doses of blinded ipilimumab with paclitaxel/carboplatin on a 3-week schedule. The initial 4 doses consisted of active ipilimumab with paclitaxel/carboplatin, and the last 2 doses consisted of placebo ipilimumab with paclitaxel/carboplatin. Ipilimumab, 10 mg/kg, was administered intravenously (IV) as a single dose over 90 minutes. Participants who did not progress or experience intolerable toxicity during the treatment phase were allowed to continue in the maintenance phase, receiving additional (blinded) ipilimumab at a dose of 10 mg/kg administered intravenously (IV) over 90 minutes every 12 weeks starting 24 weeks after the first dose until immune-related progressive disease (irPD), drug intolerance, withdrawal of consent, pregnancy, death, loss to follow up, or study closure ...https://clinicaltrials.gov/ct2/show/results/NCT00527735?sect=X4015&view=results
Effects of interferons and tumour necrosis factor-a on human lung cancer cell lines and the development of an interferon...
Effects of interferons and tumour necrosis factor-a on human lung cancer cell lines and the development of an interferon-resistant lung cancer cell line. ...http://uu.diva-portal.org/smash/record.jsf?pid=diva2:85331
Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer - Full Text View...
Inclusion Criteria:. Histologic diagnosis of non small cell lung cancer. Relapsed or unresectable stage IIIB or IV disease. One and only one prior cytotoxic chemotherapy regimen which must have included a platinum agent dosed at 60 mg/m2 or higher per cycle for cisplatin and AUC 6 per cycle for carboplatin. Documented response of at least stable disease while on first line therapy. Adult (18 years of age or older) patients. Adequate hematologic function (ANC greater than 1500 cells/mm3 and platelets greater than 100,000/mm3). Serum creatinine less than 2.0 mg/dL. Total bilirubin less than 1.5 mg/dL; SGOT and SGPT less than 3 times the upper limit of institutional normal values. ECOG performance status of 0 - 2. Bidimensional measurable or clinically evaluable disease. Patients who have signed an IRB / Ethics Committee approved informed consent. Life expectancy at least 12 weeks. Patient has fully recovered from any previous surgery (at least 4 weeks since major surgery). Patient has a ...https://clinicaltrials.gov/ct2/show/NCT00034164
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR)...
Advanced stage lung cancer is generally treated with anti-cancer medication called chemotherapy. Most lung cancer is caused by cigarette smoking. However, some lung cancers develop in people who never smoked or who only smoked for a short period of time. This type of lung cancer may respond to a medication called erlotinib (Tarceva). Erlotinib is an anticancer pill that is approved by the Food and Drug Administration (FDA) for use in patients with advanced lung cancer. Unfortunately, erlotinib does not work for all patients or only works for a period of time. The doctors are trying to find ways to improve the effect of erlotinib by combining it with another anti-cancer medication.. Ascenta Therapeutics, Inc. has developed a drug called AT-101 as a potential treatment for cancer. AT-101 is an investigational drug. That means that AT-101 is not approved by the United States Food and Drug Administration (FDA) for general use. ...https://clinicaltrials.gov/ct2/show/NCT00988169
Los Angeles Mesothelioma Lawyer Directory: Does Lung Cancer Have a Gender Bias?
peak seen in female lung cancer rates. Male lung cancer rates peaked in 1984 … can get lung cancer. In fact, about two thirds of lung cancer diagnoses are … of lung cancer: small cell lung cancer, and the more common non-small cell lung cancer (NSCLC … are dying of lung cancer, yet few women identify lung cancer as a serious ...http://losangelesmesotheliomalawyerdirectory.blogspot.com/2016/05/does-lung-cancer-have-gender-bias.html
Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy - Full Text...
The study is designed for patients with non small cell lung cancer whose cancer is too advanced and therefore cannot be operated with the goal of completely removing the cancer. At this stage of the disease, most patients cannot be cured from the disease, however, treatment can help to live longer and better by keeping the cancer under control. For that purpose, patients traditionally receive radiation therapy or chemotherapy or both treatments in succession. Recently, the administration of both treatment methods given concurrently showed somewhat better results when compared to successive administration. In some studies the drug Taxotere together with radiation performed well in keeping the cancer better under control.. Combination of the drug Taxotere together with a compound called 5-FU either as continuous infusion or in its oral form of a pill called 'Xeloda' enhanced its anti cancer activity substantially.. One goal of this study is to investigate how much of the combination can be ...https://clinicaltrials.gov/ct2/show/NCT00256841
CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to Erlotinib via transcriptional regulation of...
CUL4A has been proposed as oncogene in several types of human cancer, but its clinical significance and functional role in human non-small cell lung cancer (NSCLC) remain unclear. Expression level of CUL4A was examined by RT-PCR and Western blot. Forced expression of CUL4A was mediated by retroviruses, and CUL4A silencing by shRNAs expressing lentiviruses. Growth capacity of lung cancer cells was measured by MTT in vitro and tumorigenesis in vivo, respectively. We found that CUL4A was highly expressed in human lung cancer tissues and lung cancer cell lines, and this elevated expression positively correlated with disease progression and prognosis. Overexpression of CUL4A in human lung cancer cell lines increased cell proliferation, inhibited apoptosis, and subsequently conferred resistance to chemotherapy. On other hand, silencing CUL4A expression in NSCLC cells reduced proliferation, promoted apoptosis and resulted in tumor ...https://www.osti.gov/pages/biblio/1257383-cul4a-overexpression-enhances-lung-tumor-growth-sensitizes-lung-cancer-cells-erlotinib-via-transcriptional-regulation-egfr
Five-year Survival Rate For Nivolumab-treated Advanced Lung Cancer Patients Much Higher Than Historical Rate
WASHINGTON - Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data from a phase I clincal trial presented here at the AACR Annual Meeting 2017, April 1-5.. According to the National Cancer Institute's SEER data, five-year survival rate for patients with advanced lung and bronchus cancer is 4.3 percent, and for those with advanced NSCLC, it is 4.9 percent.. "This is the first report of the long-term survival rate in patients with metastatic NSCLC treated with an immune checkpoint inhibitor. Our study results show that for a small subset of patients, immunotherapy can work for a very long time," said Julie Brahmer, MD, associate professor of oncology at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins.. "The five-year overall survival rate reported in this study is much higher than what ...http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=1031
Outcomes in patients with non small cell lung cancer treated with Erlotinib or Afatinib:a real world,retrospective study -...
The purpose of this study is to understand real world outcomes in patients with non small cell lung cancer treated with Erlotinib or Afatinib.http://adisinsight.springer.com/trials/700285743?error=cookies_not_supported&code=7c47ef0d-7397-4615-ad8e-908d68375703
Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov
Background:. - Research has shown that the Epidermal Growth Factor Receptor (EGFR) gene is an important target for personalized lung cancer treatment. Individuals who have mutations in the EGFR gene have better responses when treated with certain personalized or targeted therapies compared with conventional chemotherapy. These mutations are more frequent in females with lung cancer who have never smoked, and different ethnic groups have different levels of frequency of the mutations. Researchers are interested in collecting more information on EGFR genetic mutations in Hispanics/Latinos with lung cancer, comparing the frequency of these mutations in males and females and smokers and nonsmokers. This study may lead to better, more personalized care approaches for all individuals with lung cancer.. Objectives:. - To study the frequency of Epidermal Growth Factor Receptor mutations in Hispanic/Latino individuals who have been diagnosed with ...https://clinicaltrials.gov/ct2/show/NCT01255150
Relevance of loss of heterozigosity in chromosome 3p in non small cell lung carcinoma as prognostic factor
Recent advances on carcinogenesis have led to the recognition of different patterns of behaviour of non-small cell lung cancers appart from those guided by the TNM staging system and the histologic subtype. The frequent genetic loss on chromosome 3p in all kinds of lung carcinoma leads to the suspect of the presence of a tumor suppresor gene located in that place. The aim of this work was to compare the different clinical features and evolution after treatment of the patients with non small cell lung carcinoma with and without loss of heterozigosity (LOH) on 3p ...http://abacus.universidadeuropea.es/handle/11268/5884
MedGen for PubMed (Select 21831955) - MedGen - NCBI
Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are nonsmall cell lung cancer and small cell lung cancer (see 182280), which account for 85% and 15% of all lung cancers, respectively. Nonsmall cell lung cancer can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. Cigarette smoking causes all types of lung cancer, but it is most strongly linked with small cell lung cancer and squamous cell carcinoma. Adenocarcinoma is the most common type in patients who have never smoked. Nonsmall cell lung cancer is often diagnosed at an advanced stage and has a poor prognosis (summary by Herbst et al., 2008). [from GTR] ...https://www.ncbi.nlm.nih.gov/medgen?LinkName=pubmed_medgen&from_uid=21831955
Lung Cancer, Lung Cancer Treatment, Lung Cancer Alternative Medicine, Lung Cancer Alternative Treatment, Lung Cancer Neuro...
Lung Cancer Treatment of Alternative Lung Cancer Alternative Neuro Acupuncture Treatment and Lung Cancer Herbal Herbs Alternative Medicine Treatment on Lung Cancer Treatment Medical Center Lung Cancer Remedieshttp://www.thetole.com/LungCancerTreatmentCure.html
Lung Cancer | CancerQuest
Ras. Ras is an oncogene that is altered in up to 30% of non small cell lung cancers (NSCLC).17 The ras protein is involved in transmitting signals through the cell that drive the cell into the division process. Learn more about Ras. Myc. The Myc family of oncogenes that are expressed abnormally in many types of cancer, including lung cancer. The myc protein acts as a transcription factor to regulate the expression of several genes. Learn more about transcription and transcription factors. Myc protein expression is altered in up to 80% of small cell lung cancers (SCLC).17Learn more about Myc. Rb. The retinoblastoma gene (Rb) is a tumor suppressor altered in up to 90% of small cell lung cancers (SCLC).17Learn more about tumor suppressors The Rb protein interacts with transcription factors to indirectly control cell division. Learn more about Rb. TP53. TP53 (or P53) is a tumor suppressor gene altered in up to 50% of non small cell ...https://www.cancerquest.org/patients/cancer-type/lung-cancer
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer - AdisInsight
Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer.http://adisinsight.springer.com/trials/700267378?error=cookies_not_supported&code=4f40a442-137b-4856-a96d-26d345fe6a94
Non-small Cell Lung Cancer Study US75 (Z-PACT) - Full Text View - ClinicalTrials.gov
This study will evaluate the effects of an investigational drug in combination with chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. This study will measure the effects of this combination on progression of lung cancer, cancer response to treatments, and development of cancer-related bone lesions ...https://clinicaltrials.gov/show/NCT00093717
Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain...
Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation : Brain metastases occur in 30-50% of Non-small cell lung cancer (NSCLC) patients and confer a worse prognosis and quality of life. These patients are usually treated with Whole-brain radiotherapy (WBRT) followed by systemic therapy. Few studies have evaluated the role of chemoradiotherapy to the primary tumor after WBRT as definitive treatment in the management of these patients. Methods Wehttp://www.youscribe.com/catalogue/documents/savoirs/long-term-survival-in-patients-with-non-small-cell-lung-cancer-and-2026401
Tarceva Doubles Progression-Free Survival in European Lung Cancer Study - UNM Comprehensive Cancer Center
The targeted agent Tarceva® (erlotinib) nearly doubles progression-free survival compared with chemotherapy when used as initial treatment for advanced non-small cell lung cancer that contains an EGFR gene mutation. These results were recently presented at the 14th World Conference on Lung Cancer.. As cancer research has evolved, it's become apparent that the specific characteristics of a tumor can have a profound effect on the behavior of the cancer and its response to particular treatments. In the case of non-small cell lung cancer (NSCLC), for example, mutations in the EGFR (epidermal growth factor receptor) gene may influence whether the cancer responds to the EGFR-targeted drugs such as Tarceva. Among people with NSCLC, EGFR mutations are most common in people of Asian ethnicity, women, never-smokers, and those with a type of lung cancer known as adenocarcinoma.. Tarceva is currently approved for the treatment of advanced NSCLC after ...http://cancer.unm.edu/2011/08/15/tarceva-doubles-progression-free-survival-in-european-lung-cancer-study/